Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hizentra in Myasthenia Gravis
NCT02100969Phase 2Completed
- Start
- May 2015
- Primary completion
- Nov 2017
- Modality
- Biologic
- Countries
- 2
01
Overview
A Phase 2 trial of polyvalent human immunoglobulin in myasthenia gravis (MG). Started May 2015; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT02100969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02100969.